Fasting and post-glucose load--reference limits for peripheral venous plasma glucose concentration in pregnant women.
Recently both the American Diabetes Organization (ADA) and World Health Organization (WHO) have revised the diagnostic recommendations for gestational diabetes mellitus (GDM), however, they did not not reach agreement on the criteria for diagnosis, the referral criteria for the confirmatory oral glucose tolerance test (OGTT), its standardization, and diagnostic cut-off point. The aims of this study were to investigate if the fasting venous plasma glucose mmol/l (f-vPG) and the 2-hour venous plasma glucose mmol/l (2h-vPG) after a WHO standardized 75 g oral glucose tolerance test (OGTT) in a non-risk group of pregnant women during first and third trimester of pregnancy deviated from that of risk groups, to establish a reference interval for f-vPG and 2h-vPG, and to investigate the predictive role of f-vPG for the 2h-vPG glucose concentration. This is a population-based case-control study where a consecutive number of pregnant women were invited to screening irrespective of their risk factors for GDM. All women filled in a questionnaire of the Danish national screening program on risk factors and had f-vPG and the 2h-vPG measured. By ruling out women with GDM and risk factors, we isolated a non-risk reference class. The In f-vPG parametric 97.5 centile was less than 5% higher during week 32 of pregnancy than during week 20, and therefore these groups were combined. The f-vPG 95% reference interval was from 4.01 mmol/l (95% CI: 3.96 to 4.07 mmol/l) to 5.26 mmol/l (95% CI: 5.19 to 5.34 mmol/l). "The true upper normal limit", the 99.9 centile, was 5.69 mmol/l (95% CI: 5.59 to 5.80 mmol/l). The f-vPG was 0.6 mmol/l lower over the whole range in pregnant women compared to age-matched non-pregnant women. The distribution of 2h-vPG concentrations at week 20 was non-Gaussian and therefore considered non-homogeneous, while it was Gaussian distributed and homogeneous at week 32. The 2h-vPG 95% reference interval of the combined weeks was from 2.80 mmol/l (95% CI: 2.56 to 3.04 mmol/l) to 7.58 mmol/l (95% CI: 7.34 to 7.82 mmol/l), and the upper limit of normal (99.9 centile) was 8.96 mmol/l (95% CI: 8.63 to 9.29 mmol/l). Distributions of f-vPG and 2h-vPG were distinct in our defined risk classes. In individual cases, no systematic correlation was found between the f-vPG concentration at week 20 and week 32. The f-vPG concentrations at any of the weeks did not predict the 2h-vPG level and no single clinical risk factor was decisive for the presence of GDM.
Jørgensen
Lone G M
LG
Department of Clinical Biochemistry, Vejle County Hospital, Vejle, Denmark. lgmj@ofir.dk
Schytte
Tine
T
Brandslund
Ivan
I
Stahl
Marta
M
Petersen
Per Hyltoft
PH
Andersen
Bent
B
D001786:Blood Glucose / Q000032:analysis*; D002624:Chemistry, Clinical / Q000379:methods; D016640:Diabetes, Gestational / Q000097:blood* / Q000175:diagnosis*; D005215:Fasting; D005260:Female; D005951:Glucose Tolerance Test / Q000379:methods*; D006801:Humans; D015233:Models, Statistical; D016011:Normal Distribution; D011237:Predictive Value of Tests; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D011263:Pregnancy Trimester, Third; D011446:Prospective Studies; D012016:Reference Values; D012307:Risk Factors; D013997:Time Factors
D001786:Blood Glucose